Abstract：Objective: To investigate the effects of different thrombolytic time of ateplase on serum peroxidoreduct protein 1 (PRDX1) and lysophosphatidic acid (LPA) in patients with acute ischemic stroke. Methods: 400 cases of acute ischemic stroke patients admitted to our hospital from June 2013 to June 2018 were selected as the study subjects, among them, 150 patients with onset to administration time < 3h were set as group A. 130 patients who were given medicine for 3~4.5h were set as group B. 120 patients received routine treatment at > 4.5h from onset to hospitalization were set as group C. Observe the clinical effect after treatment, serum PRDX1, LPA level, obstruction recanalization, 1 month after treatment three sets of the scale for assessment of modified Barthel index (MBI) evaluation of daily life activities ability, the United States national institutes of health stroke scale (NIHSS) scores. Results: After treatment, the total clinical efficacy rate of group A was 88.00% higher than 70.77% of group B and 53.33% of group C (P<0.05). There was no significant difference in serum PRDX1 and LPA between the three groups before treatment. After treatment, serum PRDX1 and LPA levels of the three groups decreased significantly, and serum PRDX1 and LPA levels of group A were significantly lower than those of group B and group C (P<0.05). After treatment, the good rate of vascular recanalization in group A was 78.00%, significantly higher than 58.46% in group B and 42.50% in group C (P<0.05). There was no significant difference in NIHSS and MBI scores between the three groups before treatment. After treatment, the MBI score of the three groups increased significantly, and the NIHSS score decreased significantly. Moreover, the MBI score of group A was significantly higher than that of group B and group C, and the NIHSS score was significantly lower than that of group B and group C (P<0.05). Conclusion: The early use of atpase in patients with acute ischemic stroke has a significant effect, which can improve the serum PRDX1 and LPA levels and quality of life of patients, which is worthy of clinical promotion.
何元发, 曹群, 高红安. 阿替普酶不同溶栓时间对急性缺血性脑卒中患者血清PRDX1 LPA的影响及疗效探究[J]. 河北医学, 2019, 25(1): 127-130.
HE Yuanfa, CAO Qun, GAO Hong'an. Exploration on Curative Effect of Different Thrombolytic Time of Ateplase on Serum PRDX1 and LPA in patients with Acute Ischemic Stroke. HeBei Med, 2019, 25(1): 127-130.
[1] 常红,许亚红,陈琳.缺血性脑卒中患者阿替普酶静脉溶栓出血并发症的研究进展[J].中华护理杂志,2015,50(4):459~462. [2] Wahlgren N, Moreira T, Michel P, et al. Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN[J]. International Journal of Stroke, 2016, 11(1):134~147. [3] Demaerschalk B M, Kleindorfer D O, Adeoye O M, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the american heart association/american stroke association[J]. Stroke, 2016, 47(2):581~641. [4] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中国全科医学,2011,14(35):4013~4017. [5] 卢昌均,韦冰心.血清生长分化因子-15水平与急性缺血性脑卒中的相关性研究[J].中国循环杂志,2015,30(9):872~874. [6] Anderson C S, Woodward M, Chalmers J. More on low-dose versus standard-dose intravenous alteplase in acute ischemic stroke.[J]. N Engl Med, 2016, 374(24):2313~2323. [7] Zivanovic Z, Adamovic D, Lucic-Prokin A, et al. Outcome of intravenous thrombolysis for acute ischemic stroke in patients with and without atrial fibrillation[J]. Medicinski Pregled, 2017, 70(7-8):203~208. [8] 李在坡,李娇娇,李娟,等.急性缺血性脑卒中患者血清PARK7、D-D、LPA水平变化及意义[J].山东医药,2017,57(44):58~60. [9] 欧阳取平,李亚梅.不同时间窗阿替普酶静脉溶栓治疗急性脑梗死患者的临床分析[J].中华老年心脑血管病杂志,2014,16(9):984~985.
2019, Vol. 25 
冀公网安备13080202000677号